Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 12:20 save search
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Published: 2023-10-22 (Crawled : 12:20) - globenewswire.com
HOOK | $0.8396 9.75% 9.8M
|
Health Technology
| Email alert
Add to watchlist
hb-200 pharma congress treatment medical
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published: 2023-08-17 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.166 -1.19% 31M
|
Health Technology
|
| O: -4.06%
H: 0.41%
C: -2.97%
diarrhea health cancer treatment family crofelemer trial
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published: 2023-08-16 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.166 -1.19% 31M
|
Health Technology
|
| O: 6.57%
H: 0.0%
C: 0.0%
diarrhea indicate world sclerosis treatment pharmaceuticals potential
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
VRCA | $6.75 -1.46% 69K
|
Health Technology
|
| O: -1.28%
H: 3.16%
C: -1.12%
vp-315 cell treatment pharmaceuticals
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | News | $0.209 -0.48% 41K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Published: 2023-07-27 (Crawled : 12:20) - globenewswire.com
FBIO | $1.785 -1.38% 98K
|
Health Technology
|
| O: 2.6%
H: 0.37%
C: -4.38%
ATXI | $0.0931 -30.52% 10M
|
Health Technology
|
| O: 3.7%
H: 1.79%
C: -6.25%
aj201 treatment trial therapeutics
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-07-26 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.166 -1.19% 31M
|
Health Technology
|
| O: 2.57%
H: 11.58%
C: 6.27%
diarrhea health approval treatment trial
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $48.875 -0.24% 11M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
DERM | $3.52 -0.57% 49K
|
|
| O: 0.35%
H: 4.91%
C: -17.19%
FBIO | $1.785 -1.38% 98K
|
Health Technology
|
| O: -0.61%
H: 3.47%
C: -1.77%
dfd-29 corporation positive treatment trials topline medical results
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
AKTX | $1.25 3.31% 4.1K
|
Health Technology
|
| O: 0.0%
H: 2.78%
C: 0.0%
update treatment therapeutics
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Published: 2023-06-29 (Crawled : 12:20) - ir.voyagertherapeutics.com
VYGR | News | $7.47 -2.35% 170K
|
Health Technology
|
| O: 0.34%
H: 3.31%
C: -3.46%
SGMO | News | $0.4989 -4.22% 880K
|
Health Technology
|
| O: 0.0%
H: 5.0%
C: 4.17%
disease license treatment therapeutics agreement
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism
Published: 2023-06-26 (Crawled : 12:20) - biospace.com/
TWST | $30.35 -3.65% 780K
|
Health Technology
|
| O: 0.0%
H: 3.07%
C: 1.97%
antibody bioscience treatment preclinical diabetes potential
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
Published: 2023-06-22 (Crawled : 12:20) - globenewswire.com
KYMR | $35.52 -0.53% 180K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.91%
kt-253 fda drug treatment designation leukemia therapeutics
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-05 (Crawled : 12:20) - globenewswire.com
PRTG | $0.265 9.23% 180K
|
Mining, Quarrying, and Oil and ...
|
| O: 2.47%
H: 17.65%
C: 0.8%
lung melanoma biotech cancer cell treatment meeting trial
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023
Published: 2023-06-03 (Crawled : 12:20) - globenewswire.com
ZVRA | $4.53 -1.09% 90K
|
n/a
| Email alert
Add to watchlist
kp1077 beyond treatment trial therapeutics
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
Published: 2023-05-23 (Crawled : 12:20) - globenewswire.com
STIM | $3.73 -3.37% 12K
|
Health Technology
|
| O: -1.09%
H: 4.8%
C: 0.0%
barometer depression treatment
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
Published: 2023-05-19 (Crawled : 12:20) - globenewswire.com
ABT | News | $106.74 -0.79% 3.3M
|
Health Technology
|
| O: 0.47%
H: 0.92%
C: -0.05%
STXS | News | $2.455 -4.1% 140K
|
Health Technology
|
| O: 8.88%
H: 29.35%
C: 22.28%
treatment global collaboration heart
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
Published: 2023-05-01 (Crawled : 12:20) - biospace.com/
BHC | $8.5 -0.35% 810K
|
Health Technology
|
| O: 0.14%
H: 3.66%
C: 1.76%
idp-126 drug food treatment gel application acne
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.